New Optimer contract to develop bioanalytical tools for RNA therapy

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company.

GH-21 by HUYA Bioscience International for Non-Small Cell Lung Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

April 20, 2024

Promising Debut for CRISPR Gene Editing Therapy for LDL Lowering

PHILADELPHIA — A DNA base editing therapy, intended for lifelong lowering of LDL cholesterol, passed initial tests in people with severe, advanced atherosclerotic cardiovascular disease

November 13, 2023

5 air quality biotech companies making an impact

Whether it be indoor or outdoor air quality, there certainly seems to be a growing number of biotech companies looking to tackle air quality issues,

June 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.